Marinus Pharmaceuticals, Inc.
MRNS · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 6% | 4.9% | 6.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 91.6% | 89.1% | 88.4% | 85.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -246.8% | -385.7% | -445.3% | -519.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -283.6% | -444.7% | -503.6% | -580.9% |
| EPS Diluted | -0.42 | -0.63 | -0.68 | -0.74 |
| % Growth | 33.3% | 7.4% | 8.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |